APR 15, 2021 9:20 AM PDT

Magic Mushroom Therapy and Antidepressants Produce Similar Results

WRITTEN BY: Annie Lennon

In recent years, psilocybin (the psychoactive ingredient in 'magic mushrooms') has gained increasing amounts of media attention following clinical trials demonstrating its ability to treat depression. Now, a new study by Imperial College London has found that, over a six-week period, psilocybin has similar effects on depression to antidepressant escitalopram. 

For the study, the researchers enrolled 59 patients suffering from long-standing, moderate-to-severe major depressive disorder. One group of 30 participants were assigned to receive two doses of 25mg of psilocybin three weeks apart alongside six weeks of a daily placebo. Meanwhile, another group of 29 participants received two doses of 1 mg psilocybin three weeks apart alongside six weeks of daily oral escitalopram, a selective serotonin reuptake inhibitor (SSRI). 

The researchers assessed how these treatments, conducted over a 6-week period, affected patients' scores for depression on the 16-item Quick Inventory for Depressive Symptomatology-Self Report. The inventory scores patients from 0 to 27, 27 indicating more severe depression and remission characterized by a score lower than 5. 

All in all, the trial did not show a significant difference in depression scores between those on psilocybin and those on escitalopram. Those in the psilocybin group had a mean difference in score or -8 compared to -6 for those treated with escitalopram. Although secondary outcomes (reduction in score of over 50%) were generally more common in the psilocybin group, analyses of these outcomes lacked correction for multiple comparisons and thus should not be over-interpreted. 

The researchers nevertheless say that these results signal hope for the potential of psilocybin-assisted psychotherapy to treat depression. To understand how the treatment may give maximum benefit to patients, however, and how it differs from more conventional treatments, larger and longer trials are required. 

 

Sources: The New England Journal of MedicineThe Guardian

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
OCT 12, 2021
Immunology
Major Landmark in a 100-Year Search for a Malaria Vaccine
OCT 12, 2021
Major Landmark in a 100-Year Search for a Malaria Vaccine
In one of the greatest global health milestones of our time, the World Health Organization has approved the widespread d ...
OCT 14, 2021
Drug Discovery & Development
Itchy, red, dry eyes? FDA approves monthly implant for allergic conjunctivitis
OCT 14, 2021
Itchy, red, dry eyes? FDA approves monthly implant for allergic conjunctivitis
The conjunctiva is a thin membrane that covers the front of the eyes and the inner eyelids. The conjunctiva produces tea ...
OCT 26, 2021
Immunology
Two Different Arms, Twice the Cancer-Killing Potential?
OCT 26, 2021
Two Different Arms, Twice the Cancer-Killing Potential?
Our immune system has developed an arsenal of sophisticated molecular weapons to defend us against the continuous barrag ...
OCT 24, 2021
Microbiology
New Treatment Approach Uses Bacteria to Deliver Drugs to Cancer Cells
OCT 24, 2021
New Treatment Approach Uses Bacteria to Deliver Drugs to Cancer Cells
Bacteria can be found almost everywhere, and they can serve many beneficial purposes. Scientists are now using bacterial ...
NOV 05, 2021
Cannabis Sciences
THC & ASD: A Crucial Contributor to Symptom Alleviation
NOV 05, 2021
THC & ASD: A Crucial Contributor to Symptom Alleviation
Up until recently, cannabis-based treatments for Autism Spectrum Disorder (ASD) have focused on CBD-enrichment and THC d ...
NOV 14, 2021
Genetics & Genomics
Cancer Drug Target Could Actually Worsen Disease
NOV 14, 2021
Cancer Drug Target Could Actually Worsen Disease
Cancer drugs have been developed that target an enzyme, Shp2. But that enzyme has a more complex role than we knew.
Loading Comments...